A European randomised multicentre study of interferon alpha-2b versus no treatment after intensive therapy and Autologous hematopoeitic Stem Cell Transplantation (ASCT) for relapsing lymphoma patients
Completed
- Conditions
- ymphoma (Hodgkin's), Lymphoma (non-Hodgkin's)CancerLymphoma
- Registration Number
- ISRCTN46751362
- Lead Sponsor
- Schering-Plough Ltd (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients with histologically proven non-Hodgkin's lymphoma or Hodgkin's disease, in first relapse or first progression responding to salvage regimen, and treated with high dose therapy and ASCT
2. Normal renal and hepatic function.
3. Eastern Cooperative Oncology Group (ECOG) performance status zero to three
4. Aged 18 to 65 years
5. No history of prior or concomitant malignancy except for treated (surgery or radiotherapy) basal cell carcinoma of the skin or carcinoma in situ, whatever the site
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration